Sugi Predict

Sugi Predict / Targets / PPP2R2A

PPP2R2A

Serine/threonine-protein phosphatase 2A 55 kDa regulatory subunit B alpha isoform · P63151 · PPP2R2A on Sugi Atlas →

56 patent compounds predicted against PPP2R2A, 52 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
Microcystin-Lr Microcystin-Lr (SCHEMBL21245230) 1.00 1/20
Microcystin-Lr Microcystin-Lr (SCHEMBL21245231) 1.00 1/20
Microcystin-Lr Microcystin-Lr (SCHEMBL29349513) 1.00 1/20
SCHEMBL29897131 SCHEMBL29897131 1.00 1/20
SCHEMBL29350595 SCHEMBL29350595 0.95 1/20
SCHEMBL29350648 SCHEMBL29350648 0.95 1/20
SCHEMBL29711569 SCHEMBL29711569 0.95 1/20
SCHEMBL29777431 SCHEMBL29777431 0.95 1/20
SCHEMBL31005304 SCHEMBL31005304 0.95 1/20
SCHEMBL27316275 SCHEMBL27316275 0.94 1/20
SCHEMBL30788332 SCHEMBL30788332 0.92 1/20
SCHEMBL30788333 SCHEMBL30788333 0.92 1/20
SCHEMBL38650007 SCHEMBL38650007 0.92 1/20
SCHEMBL29793867 SCHEMBL29793867 0.92 1/20
SCHEMBL30859111 SCHEMBL30859111 0.91 1/20
SCHEMBL29793992 SCHEMBL29793992 0.90 1/20
SCHEMBL29349519 SCHEMBL29349519 0.89 1/20
SCHEMBL29598261 SCHEMBL29598261 0.89 1/20
SCHEMBL30027122 SCHEMBL30027122 0.89 1/20
SCHEMBL29507045 SCHEMBL29507045 0.88 1/20

Clinical trials — most relevant to PPP2R2A by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Rectal Tacrolimus in the Treatment of Resistant Ulcerative Proctitis PHASE4COMPLETED
Efficacy and Safety of 0.25% Timolol Gel in Healing Surgical Open Wounds PHASE2/PHASE3COMPLETED
The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus PHASE3UNKNOWN
Treatment With HMG-COA Reductase Inhibitor of Growth and Bone Abnormalities in Children With Noonan Syndrome PHASE3COMPLETED
Study Evaluating Toxicity & Efficacy of Lenalidomide(Revlimid®)in Chemotherapy-Naïve AIPC Patients PHASE2COMPLETED
Everolimus in Treating Patients With Relapsed or Refractory Multiple Myeloma PHASE2COMPLETED
Cixutumumab and Temsirolimus in Treating Patients With Metastatic Prostate Cancer PHASE1/PHASE2COMPLETED
Open-label Study on Treatment of Primary Aldosteronism With Everolimus PHASE2COMPLETED
Everolimus for Children With Recurrent or Progressive Ependymoma PHASE2COMPLETED
The Phosphodiesterase 4 Inhibitor Roflumilast as an Adjunct to Antidepressants in Major Depressive Disorder Patients PHASE1/PHASE2WITHDRAWN
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma PHASE1COMPLETED
Evaluating MED2005 & Nitrostat Bioavailability PHASE1COMPLETED
Bioequivalence Study of Tacrolimus in Healthy Volunteers PHASE1COMPLETED
Palliative Thoracic Radiotherapy Plus BKM120 PHASE1COMPLETED
Quantification of GADD34 Expression in RA nanCOMPLETED
Immune Signature of Palmoplantar Pustulosis nanCOMPLETED
Lymphoid Tyrosine Phosphatase Gene Polymorphisms in Inflammatory Bowel Disease nanUNKNOWN
Hemodynamic Assessment of underLying myocyTe Function in Right Heart Failure nanRECRUITING
Duality of Lipids: the Athlete's Paradox nanCOMPLETED
Severe Insulin Resistance in Patients With Type 2 Diabetes nanCOMPLETED
Role of Amino Acids and Genetic Disorder in Pathogenesis of Heart Failure nanUNKNOWN
The Effect Of DAAs on miRNA-122 And Insulin Resistance In Chronic HCV Patients nanUNKNOWN
Cardiovascular Effects of Empagliflozine nanUNKNOWN
Studies of the Tumour Suppressor Gene PTEN - Endometrial Cancer nanCOMPLETED
NGS in Gallbladder Cancer and Response to Treatment nanRECRUITING
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus nanCOMPLETED
Phosphoproteomic Profile of Children With Down Syndrome nanCOMPLETED
IVF Outcome in Polycystic Ovary Syndrome Patients nanUNKNOWN
Vulvodynia: Identification of Potential Relevant Biomarkers nanCOMPLETED
99Tc-MDP in Postmenopausal Women With Differentiated Thyroid Cancer and Osteoporosis nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a PPP2R2A binder may also engage these)

ProteinNameSimilarity
Q6P1F6 — 1.000 Q6P1F6 →
P36876 — 1.000 P36876 →
B6VA23 — 1.000 B6VA23 →
Q925E7 — 1.000 Q925E7 →
P63150 — 1.000 P63150 →
Q4R7Z4 — 1.000 Q4R7Z4 →
Q29090 — 1.000 Q29090 →
Q5ZIY5 — 1.000 Q5ZIY5 →
P50410 — 1.000 P50410 →
P56932 — 0.997 P56932 →
Q66LE6 — 0.996 Q66LE6 →
P97888 — 0.996 P97888 →
Q6DIY3 — 0.996 Q6DIY3 →
Q6NY64 — 0.996 Q6NY64 →
Q7ZX64 — 0.995 Q7ZX64 →
Q95LP0 — 0.995 Q95LP0 →
Q9Y2T4 — 0.995 Q9Y2T4 →
P54614 — 0.993 P54614 →
Q8BG02 — 0.993 Q8BG02 →
A1L3L9 — 0.988 A1L3L9 →
Q0D2F4 — 0.988 Q0D2F4 →
Q4R8L3 — 0.987 Q4R8L3 →
Q6ZWR4 — 0.987 Q6ZWR4 →
Q5R4A2 — 0.986 Q5R4A2 →
P36877 — 0.986 P36877 →
Q00005 — 0.983 Q00005 →
Q5E9Q7 — 0.983 Q5E9Q7 →
Q0E2P1 — 0.981 Q0E2P1 →
Q39247 — 0.981 Q39247 →
A2X2K3 — 0.978 A2X2K3 →